Compositions and methods for blocking sodium channels

Abstract

The disclosure provides methods for treating a subject suffering from a disease associated with sodium channel activity. The method comprises administering to the subject a therapeutically effective amount of a compound according to Formula II or Formula III described in the specification, or a pharmaceutically acceptable salt, prodrug, tautomer, stereoisomer, hydrate, or solvate thereof.

We claim: 
     
       1. A method for treating a subject suffering from epilepsy, the method comprising administering to the subject a therapeutically effective amount of a compound according to Formula II, or a pharmaceutically acceptable salt, prodrug, tautomer, stereoisomer, hydrate, or solvate thereof: 
       
         
           
           
               
               
           
         
         wherein
 R1, R2, R3, R4, R5, R8 and R12 in each occurrence is independently H, CH 3 , F, Cl, Br, I, OCH 3 , CF 3 , OCF 3 , NH 2 , COOH, CHO, OH, SH, NO 2 , COCH 3 , CONH 2 , or NHCOCH 3 ; 
 R9, R10 and R11 each is independently H, CH 3 , F, Cl, Br, I, OCH 3 , CF 3 , OCF 3 , NH 2 , COOH, CHO, OH, SH, NO 2 , COCH 3 , CONH 2 , NHCOCH 3 , or 
 
       
       
         
           
           
               
               
           
         
       
       and
 R13 is optionally substituted C 1 -C 6  alkyl, optionally substituted C 1 -C 6  haloalkyl, or halogen. 
 
     
     
       2. The method of  claim 1 , wherein R13 is optionally substituted C 1 -C 6  alkyl. 
     
     
       3. The method of  claim 2 , wherein R13 is CH 3 . 
     
     
       4. The method of  claim 3 , wherein the compound has the structure: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt, prodrug, tautomer, stereoisomer, hydrate, or solvate thereof. 
       
     
     
       5. The method of  claim 1 , wherein the epilepsy is partial epilepsy, generalized absence epilepsy, temporal lobe epilepsy or therapy resistant epilepsy.